Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Cetuximab + Irinotecan in mCRC
NCT00063141Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2003
- Primary completion
- Jun 2006
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of KL-140 in colorectal cancer (CRC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival. Started Apr 2003; status: completed.
02
Drugs
KL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00063141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063141.